[Liprimar in prevention of coronary complications in patients following reconstructive vascular surgery].
The article is dedicated to analyzing the outcomes of an open prospective study of efficacy of Liprimai administered in the postoperative period. The study comprised a total of 30 patients presenting with atherosclerotic lesions of the arteries of the carotid bed and aorto-femoral segment, who were subjected to reconstructive vascular operations. The aim of the present study was to look into a possibility of preventing cardiac complications in patients after endured reconstructive vascular surgery. Liprimar was administered at a daily dose of 10 mg seven days prior to the operation, and for eight days thereafter.
Pokrovskiĭ
A V
AV
Department of Vascular Surgery, A. V. Vishnevsky Institute of Surgery, Russian Academy of Medical Sciences, Moscow, Russia.
Zotikov
A E
AE
Shubin
A A
AA
Perisaev
G A
GA
Il'ina
M V
MV
Ivanov
L O
LO
Suntsov
D S
DS
Il'in
S A
SA
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002340:Carotid Artery Diseases / Q000401:mortality / Q000601:surgery*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007925:Leriche Syndrome / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care; D011446:Prospective Studies; D012720:Severity of Illness Index; D014656:Vascular Surgical Procedures / Q000379:methods*
D000924:Anticholesteremic Agents; D002784:Cholesterol